Cargando…

Differential Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Response in Inactivated Virus–Vaccinated, Convalescent, and Breakthrough-Infected Subjects

BACKGROUND: We sought to identify potential antigens for discerning between humoral responses elicited after vaccination with CoronaVac (a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] inactivated vaccine), natural infection, or breakthrough infection. METHODS: Serum samples obtained...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duarte, Luisa F, Vázquez, Yaneisi, Diethelm-Varela, Benjamín, Pavez, Valentina, Berríos-Rojas, Roslye, Méndez, Constanza, Riedel, Claudia A, White, Jessica A, Kalergis, Alexis M, Bueno, Susan M, González, Pablo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547456/ https://www.ncbi.nlm.nih.gov/pubmed/37572355 http://dx.doi.org/10.1093/infdis/jiad320

Ejemplares similares

Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
por: Duarte, Luisa F., et al.
Publicado: (2021)

Induction of Trained Immunity by Recombinant Vaccines
por: Covián, Camila, et al.
Publicado: (2021)

Characterization of the humoral and cellular immunity induced by a recombinant BCG vaccine for the respiratory syncytial virus in healthy adults
por: Pacheco, Gaspar A., et al.
Publicado: (2023)

New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus
por: Diethelm-Varela, Benjamín, et al.
Publicado: (2023)

Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
por: Hall, Victoria G, et al.
Publicado: (2023)

Molecular and Cellular Mechanisms Modulating Trained Immunity by Various Cell Types in Response to Pathogen Encounter
por: Acevedo, Orlando A., et al.
Publicado: (2021)

Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection
por: Miyakawa, Kei, et al.
Publicado: (2021)

Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
por: Méndez, Constanza, et al.
Publicado: (2023)

SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
por: Canedo-Marroquín, Gisela, et al.
Publicado: (2020)

The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses
por: Soto, Jorge A., et al.
Publicado: (2020)

Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape
por: Reyes, Humberto, et al.
Publicado: (2022)

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
por: Melo-González, Felipe, et al.
Publicado: (2021)

Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
por: Mwimanzi, Francis, et al.
Publicado: (2023)

Contribution of Gut Microbiota to Immune Tolerance in Infants
por: Méndez, Constanza S., et al.
Publicado: (2021)

A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)

Progression to Critical Illness and Death in Patients With Breakthrough Hospitalizations
por: Suleyman, Geehan, et al.
Publicado: (2022)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children
por: Soto, Jorge A., et al.
Publicado: (2022)

Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections
por: Suleyman, Geehan, et al.
Publicado: (2022)

Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
por: Gálvez, Nicolás MS, et al.
Publicado: (2022)

Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection
por: Silva, Pedro H., et al.
Publicado: (2022)

Statistical explanation of the protective effect of four COVID-19 vaccine doses in the general population
por: Reyes, Humberto, et al.
Publicado: (2023)

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023)

Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series
por: Kim, Paul S., et al.
Publicado: (2022)

A SARS-CoV-2 outbreak associated with vaccine breakthrough in an acute care hospital
por: Park, Se Yoon, et al.
Publicado: (2022)

Humoral responses to the CoronoVac vaccine in healthcare workers
por: Eyupoglu, Gokhan, et al.
Publicado: (2023)

Is there a role for HSF1 in viral infections?
por: Reyes, Antonia, et al.
Publicado: (2022)

Post-Vaccination Coronavirus Disease 2019: A Case-Control Study and Genomic Analysis of 119 Breakthrough Infections in Partially Vaccinated Individuals( )
por: Baltas, Ioannis, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Delta Vaccine Breakthrough Transmissibility in Alachua County, Florida
por: Rife Magalis, Brittany, et al.
Publicado: (2022)

Interplay between Lipid Metabolism, Lipid Droplets, and DNA Virus Infections
por: Farías, Mónica A., et al.
Publicado: (2022)

Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update
por: Vázquez, Yaneisi, et al.
Publicado: (2019)

Inactivation of surrogate coronaviruses on hard surfaces by health care germicides
por: Hulkower, Rachel L., et al.
Publicado: (2011)

Longitudinal Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus Shedding and Restricted Tissue Distribution
por: Ke, Ruian, et al.
Publicado: (2022)

Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients
por: Klapholz, Marc, et al.
Publicado: (2021)

Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study
por: Koirala, Janak, et al.
Publicado: (2021)

A Case of Long-Term Seronegative Human Immunodeficiency Virus (HIV) Infection: The Importance of the Humoral Response to HIV
por: Siemieniuk, Reed A. C., et al.
Publicado: (2015)

High Prevalence of Humoral and Cellular Immunity to Influenza Viruses in Preschool Children Living in Addis Ababa, Ethiopia
por: Dembinski, Jennifer L., et al.
Publicado: (2017)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials
por: Levine, Adam C, et al.
Publicado: (2023)

Antibody Level Predicts the Clinical Course of Breakthrough Infection of COVID-19 Caused by Delta and Omicron Variants: A Prospective Cross-Sectional Study
por: Kim, Min Hyung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j6vaqhmahudqaob4p49f40hetu